Skip to main content

Table 6 The average duration of common cold disease in patients of different virus subgroups in days

From: Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials

Patients Group hRV hCV InfA
ITT Carrageenan 8.8 ± 0.6 9.02 ± 0.7 8.7 ± 1.0
Placebo 10.7 ± 0.7 12.95 ± 0.99 12.0 ± 1.2
  Difference 1.9 days* 3.9 days** 3.3 days*
PP Carageenan 8.7 ± 0.7 9.1 ± 0.7 9 ± 1.1
Placebo 10.5 ± 0.8 12.2 ± 1.1 10.7 ± 1.5
  Difference 1.8 days* 3.1 days** 1.7 days
  1. *:p < 0.05; **:p < 0.01.